Science & Technology
Drug development of RK-33 for breast cancer treatment
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44CA295155-01A1
Award Ceiling
$1.6M
Award Floor
$1.6M
Close Date
Aug 31, 2027
534 days leftTotal Funding
$1.6M
Expected Awards
1
Posted Date
Sep 22, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44CA295155-01A1
Description
SBIR Phase Phase II award: "Drug development of RK-33 for breast cancer treatment" awarded to NATSAR PHARMACEUTICALS, INC. in ELLICOTT CITY, Maryland. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,634,811. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.